stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) EV/FCF
As of 5 November 2026, IDEAYA Biosciences, Inc. (IDYA) trades at a EV/FCF of −6.7×. Over the past ten years it has ranged from −36.9× (January 2026) to 12.3× (September 2021); the current reading is higher than 40% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −32.9× | — |
| FY2024 | −5.7× | — |
| FY2023 | −12.8× | — |
| FY2022 | −3.9× | — |
| FY2021 | −10.0× | — |
| FY2020 | 1.1× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −8.9× | — |
| Jun 2026 | −22.9× | — |
| Mar 2026 | −26.0× | — |
| Dec 2025 | −32.9× | — |
| 15 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | −73.9× |
| ELVN Enliven Therapeutics, Inc. compare | −31.3× |
| CELC Celcuity, Inc. compare | −18.4× |
| DNLI Denali Therapeutics Inc. compare | −7.2× |
| VRDN Viridian Therapeutics, Inc. compare | −7.0× |
| IDYA IDEAYA Biosciences, Inc. | −6.7× |
| DYN Dyne Therapeutics, Inc. compare | −4.6× |
| BEAM Beam Therapeutics Inc. compare | −4.5× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 124× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement